Groupama Asset Managment Sells 9,874 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Groupama Asset Management reduced its holdings in Edwards Lifesciences Corporation by 35.5%, selling 9,874 shares during the quarter, leaving them with a total of 17,935 shares valued at approximately $1.27 million.
• Various institutional investors, including Vega Investment Solutions and Quantbot Technologies LP, have initiated new stakes in Edwards Lifesciences, with institutional ownership now at 79.46%.
• Analysts have increased price targets for Edwards Lifesciences, with Deutsche Bank raising theirs from $85.00 to $94.00, supporting a majority of ratings classified as a "Moderate Buy."

Groupama Asset Managment reduced its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 35.5% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 17,935 shares of the medical research company's stock after selling 9,874 shares during the period. Groupama Asset Managment's holdings in Edwards Lifesciences were worth $1,272,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC grew its stake in shares of Edwards Lifesciences by 0.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock worth $2,170,000 after purchasing an additional 145 shares during the period. Alyeska Investment Group L.P. acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth $49,038,000. Dynamic Advisor Solutions LLC grew its stake in shares of Edwards Lifesciences by 2.4% during the first quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company's stock worth $1,124,000 after purchasing an additional 370 shares during the period. Wealth Enhancement Advisory Services LLC grew its stake in shares of Edwards Lifesciences by 13.5% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company's stock worth $5,582,000 after purchasing an additional 9,188 shares during the period. Finally, Advanced Portfolio Management LLC acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth $328,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Up 0.7%

Shares of Edwards Lifesciences stock traded up $0.5950 during trading on Friday, reaching $81.7550. The stock had a trading volume of 3,076,141 shares, compared to its average volume of 4,824,093. The company has a market capitalization of $48.00 billion, a price-to-earnings ratio of 11.76, a P/E/G ratio of 3.95 and a beta of 1.08. The stock has a fifty day moving average price of $77.58 and a two-hundred day moving average price of $74.69. Edwards Lifesciences Corporation has a 52 week low of $64.00 and a 52 week high of $83.00. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period in the previous year, the company posted $0.70 earnings per share. The company's quarterly revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Sell-side analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

EW has been the subject of a number of analyst reports. William Blair raised Edwards Lifesciences to a "strong-buy" rating in a research note on Friday, July 25th. Daiwa America upgraded Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, July 29th. Canaccord Genuity Group lifted their target price on Edwards Lifesciences from $75.00 to $81.00 and gave the stock a "hold" rating in a report on Friday, July 25th. Morgan Stanley lifted their target price on Edwards Lifesciences from $75.00 to $81.00 and gave the stock an "equal weight" rating in a report on Tuesday, July 15th. Finally, Stifel Nicolaus lifted their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a "buy" rating in a report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $85.90.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the transaction, the vice president owned 22,002 shares of the company's stock, valued at $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 2,570 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $77.40, for a total value of $198,918.00. Following the completion of the transaction, the vice president directly owned 50,356 shares in the company, valued at $3,897,554.40. The trade was a 4.86% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 24,584 shares of company stock valued at $1,897,762 over the last 90 days. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.